MedTrace Logo

To Assess Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses.

NCT01958645 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2016-02-04

Study results available
· View outcomes & findings →

Summary

A study to investigate the safety, tolerability and pharmacodynamics of MEDI8111 after single ascending doses in healthy male.

Conditions

  • Healthy Subjects

Interventions

DRUG

MEDI8111

MEDI8111 lyophilisate for solution for infusion

OTHER

Placebo

Placebo for MEDI8111 saline solution for infusion

Sponsors & Collaborators

Principal Investigators

  • Karin Wahlander, MD · AstraZeneca Mölndal, Sweden

  • Anders Berggren, MD · AstraZeneca Mölndal, Sweden

  • Timothy Mant, Prof · Quintiles London, United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01958645 on ClinicalTrials.gov